4.80

1.05% 0.05

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Why MYGN Down? Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $4.80, with a volume of 1.95M. It is up +1.05% in the last 24 hours and up +4.58% over the past month. Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Previous Close:

$4.75

Open:

$4.7

24h Volume:

1.95M

Relative Volume:

1.20

Market Cap:

$453.33M

Revenue:

$824.50M

Net Income/Loss:

$-365.90M

P/E Ratio:

-1.2142

EPS:

-3.9531

Net Cash Flow:

$-25.60M

1W Performance:

+0.42%

1M Performance:

+4.58%

6M Performance:

-40.30%

1Y Performance:

-32.68%

1-Day Range:

$4.69

$5.06

1-Week Range:

$4.55

$5.06

52-Week Range:

$3.76

$8.59

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1113)

Industry

Diagnostics & Research (51)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2026-05-05

Latest SEC Filings

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYGN Myriad Genetics Inc	4.80	453.33M	824.50M	-365.90M	-25.60M	-3.9531
TMO Thermo Fisher Scientific Inc	469.21	174.37B	45.20B	6.88B	6.75B	18.19
DHR Danaher Corp	175.15	123.97B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	567.46	45.07B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.52	32.36B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	307.12	30.15B	3.17B	642.63M	516.49M	10.77

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight
Feb-12-25	Initiated	Craig Hallum	Buy
Dec-10-24	Initiated	UBS	Neutral
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Underperform
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

May 01, 2026

Myriad Genetics introduces FirstGene Multiple Prenatal Screen at ACOG2026 with interactive experience - Traders Union

May 01, 2026

Apr 30, 2026

Only 13% say first depression medication worked, Myriad survey finds - Stock Titan

Apr 30, 2026

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan - ChartMill

Apr 30, 2026

Apr 29, 2026

MSN Money - MSN

Apr 29, 2026

Myriad Genetics to unveil advanced decision-support tools in cancer care at ASCO26 - Traders Union

Apr 29, 2026

Apr 28, 2026

After the bell on May 5, Myriad Genetics will post Q1 results - Stock Titan

Apr 28, 2026

Analysts estimate Myriad Genetics (MYGN) to report a decline in earnings: What to look out for - MSN

Apr 28, 2026

Myriad Genetics (MYGN) to Release Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Apr 28, 2026

Myriad Genetics Q3 2025 Earnings Preview - MSN

Apr 28, 2026

Apr 27, 2026

Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN

Apr 27, 2026

Myriad Genetics unveils FirstGene Multiple Prenatal Screen at Washington D.C. symposium - Traders Union

Apr 27, 2026

Small-Cap Stocks: Krispy Kreme, Myriad Genetics, and Hamilton Insurance Group to AvoidNews and Statistics - IndexBox

Apr 25, 2026

MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain? - MSN

Apr 25, 2026

Apr 23, 2026

Forbes ranks Myriad Genetics among top U.S. employers for company culture in 2026 - Traders Union

Apr 23, 2026

Apr 22, 2026

MYGN Financials: Income Statement, Balance Sheet & Cash Flow | Myriad Genetics - Stock Titan

Apr 22, 2026

EPO Biomarkers Market Outlook 2026-2033: Growth Drivers, - openPR.com

Apr 22, 2026

Apr 21, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Apr 21, 2026

Apr 16, 2026

Myriad Genetics (MYGN) to Present at AACR Annual Meeting 2026 - GuruFocus

Apr 16, 2026

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - GlobeNewswire

Apr 16, 2026

Breast cancer treatment data lead Myriad's 2 AACR podium talks - Stock Titan

Apr 16, 2026

Apr 15, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN) Sees Significant Decline in Short Interest - MarketBeat

Apr 15, 2026

Myriad Genetics (NASDAQ: MYGN) COO has 1,069 shares withheld for RSU taxes - Stock Titan

Apr 15, 2026

Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares - Stock Titan

Apr 15, 2026

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by TD Cowen - MarketBeat

Apr 15, 2026

Apr 14, 2026

[ARS] MYRIAD GENETICS INC SEC Filing - Stock Titan

Apr 14, 2026

Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan

Apr 14, 2026

Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan - National Today

Apr 14, 2026

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - Bitget

Apr 14, 2026

GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 - Yahoo Finance

Apr 14, 2026

Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN

Apr 14, 2026

Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan

Apr 14, 2026

Apr 13, 2026

Sectors Review: What is the next catalyst for Myriad Genetics IncPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn

Apr 13, 2026

Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN

Apr 13, 2026

Apr 09, 2026

Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MYRIAD GENETICS INC. lobbying was just disclosed - Quiver Quantitative

Apr 09, 2026

Myriad brings 4 SGO studies, including ovarian recurrence data - Stock Titan

Apr 09, 2026

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting - ChartMill

Apr 09, 2026

Aberdeen Group plc Purchases 246,748 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat

Apr 09, 2026

Apr 08, 2026

Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn

Apr 08, 2026

Trend Report: Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn

Apr 08, 2026

Market Outlook: Whats next for Myriad Genetics Inc stockMarket Trend Report & AI Optimized Trade Strategies - baoquankhu1.vn

Apr 08, 2026

MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill

Apr 08, 2026

Apr 07, 2026